| Joshua Agranat, MD | |
|
246 Catalina Dr, Ashland, OR 97520-1624 | |
| (541) 488-3193 | |
| Not Available |
| Full Name | Joshua Agranat |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 8 Years |
| Location | 246 Catalina Dr, Ashland, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639533888 | NPI | - | NPPES |
| 282819 | Other | MA | STATE LICENSE |
| MD207308 | Other | OR | STATE LICENSE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Asante Ashland Community Hospital | Ashland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Retina And Vitreous Center Of Southern Oregon, Pc | 5193796191 | 3 |
News Archive
A new study conducted at the Medical Research Council (MRC) Laboratory of Molecular Biology, UK, has found how wound healing is regulated by the body clock in such a way that injuries that occured at daytime heal nearly 60% faster than that at night.
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced that it has closed a private placement of its securities resulting in gross proceeds to the company of over $15 million.
A team of Australian researchers, led by University of Melbourne has developed a genetic test that is able to predict the risk of developing Autism Spectrum Disorder, ASD.
Researchers have used machine learning, a type of artificial intelligence, to develop a prediction model for the early diagnosis of opioid use disorder.
Delcath Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has responded to the Company's request made in September for a pre-New Drug Application (NDA) meeting and has scheduled a date in mid-January 2012.
› Verified 8 days ago
| Entity Name | Retina & Vitreous Center Of Southern Oregon, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700924594 PECOS PAC ID: 5193796191 Enrollment ID: O20040803001576 |
News Archive
A new study conducted at the Medical Research Council (MRC) Laboratory of Molecular Biology, UK, has found how wound healing is regulated by the body clock in such a way that injuries that occured at daytime heal nearly 60% faster than that at night.
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced that it has closed a private placement of its securities resulting in gross proceeds to the company of over $15 million.
A team of Australian researchers, led by University of Melbourne has developed a genetic test that is able to predict the risk of developing Autism Spectrum Disorder, ASD.
Researchers have used machine learning, a type of artificial intelligence, to develop a prediction model for the early diagnosis of opioid use disorder.
Delcath Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has responded to the Company's request made in September for a pre-New Drug Application (NDA) meeting and has scheduled a date in mid-January 2012.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua Agranat, MD 246 Catalina Dr, Ashland, OR 97520-1624 Ph: (541) 488-3192 | Joshua Agranat, MD 246 Catalina Dr, Ashland, OR 97520-1624 Ph: (541) 488-3193 |
News Archive
A new study conducted at the Medical Research Council (MRC) Laboratory of Molecular Biology, UK, has found how wound healing is regulated by the body clock in such a way that injuries that occured at daytime heal nearly 60% faster than that at night.
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced that it has closed a private placement of its securities resulting in gross proceeds to the company of over $15 million.
A team of Australian researchers, led by University of Melbourne has developed a genetic test that is able to predict the risk of developing Autism Spectrum Disorder, ASD.
Researchers have used machine learning, a type of artificial intelligence, to develop a prediction model for the early diagnosis of opioid use disorder.
Delcath Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has responded to the Company's request made in September for a pre-New Drug Application (NDA) meeting and has scheduled a date in mid-January 2012.
› Verified 8 days ago
Dr. Jeffrey David Welder, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 648 N Main St, Ashland, OR 97520 Phone: 541-482-8100 | |
Dr. Vivian Schiedler, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 251 Maple St, Ashland, OR 97520 Phone: 541-708-6393 Fax: 844-373-1899 | |
Dr. John David Hyatt, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 246 Catalina Dr, Ashland, OR 97520 Phone: 541-488-3192 Fax: 541-488-0646 | |
Dr. Robert Henry Ewing Jr., MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 648 N Main St, Ashland, OR 97520 Phone: 541-482-8100 Fax: 541-488-5081 | |
Dr. Christine Read Gonzales, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 246 Catalina Dr, Ashland, OR 97520 Phone: 541-488-3192 Fax: 541-488-0646 | |
Dr. William Stuart Epstein, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3530 Tolman Creek Rd, Ashland, OR 97520 Phone: 541-482-8100 Fax: 541-488-5081 |